Journalistic investigation on the gap in global access to health.
Doctors continue prescribing anti-anxiety medications such as lorazepam or diazepam for long periods despite the risk of addictions. Meanwhile, under-investment in psychological care is making things worse.
In many European countries, the availability of psychological treatment in the public healthcare system is inadequate or even non-existent. Barriers such as long waiting lists, co-payments and inadequate resources push people with anxiety or depression -those who can afford it- to the private system.
In the European Union, thousands of people with serious mental disorders live isolated and secluded from society, without receiving all the care they need. At least 150 million euros of European Union funds, intended to improve their situation, have been used for other purposes.
COVID-19 has paralysed mental health care, already weak in several European countries. During the first wave, 75% of psychiatry services were via telemedicine, but it doesn’t work for everybody.
For weeks, Spain and Italy were epicentres of the COVID-19 pandemic. Their health defences had an important gap.
The real cost that public administrations pay for CAR-T therapies is negotiated in secret, although the Ministry of Health does publish the maximum price it is willing to pay.
Together with sums of money they received from other laboratories, they were dished out a total of over 1.6 million. Most of them work in public hospitals.
All these countries publish a declared portion – how much each doctor received from each firm – and an anonymous portion, published as an aggregate figure without names. It is partial transparency.